ARS Pharmaceuticals, Inc - Asset Resilience Ratio
ARS Pharmaceuticals, Inc (SPRY) has an Asset Resilience Ratio of 62.16% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ARS Pharmaceuticals, Inc's Asset Resilience Ratio has changed over time. Check how strategically is ARS Pharmaceuticals, Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down ARS Pharmaceuticals, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SPRY stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $203.67 Million | 62.16% |
| Total Liquid Assets | $203.67 Million | 62.16% |
Asset Resilience Insights
- Very High Liquidity: ARS Pharmaceuticals, Inc maintains exceptional liquid asset reserves at 62.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ARS Pharmaceuticals, Inc Industry Peers by Asset Resilience Ratio
Compare ARS Pharmaceuticals, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Genfit S.A.
PA:GNFT |
Biotechnology | 64.01% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670 |
Biotechnology | 9.82% |
Annual Asset Resilience Ratio for ARS Pharmaceuticals, Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ARS Pharmaceuticals, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.16% | $203.67 Million | $327.65 Million | -12.79pp |
| 2024-12-31 | 74.95% | $263.20 Million | $351.15 Million | +7.46pp |
| 2023-12-31 | 67.49% | $157.39 Million | $233.19 Million | +44.80pp |
| 2022-12-31 | 22.69% | $63.86 Million | $281.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $61.45 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more